BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, May 21, 2026
View BioWorld MedTech
Home » In vivo gene editing to halt the clock before it’s too late
To read the full article sign up for free or sign in.
Genetic/congenital

In vivo gene editing to halt the clock before it’s too late

Dec. 1, 2025
By Mar de Miguel
No Comments
A 24‑week pregnant woman fears for her unborn baby, who is developing with a sacrococcygeal teratoma so large and vascularized that it nearly surpasses the size of the fetus itself. Faced with this threat, surgeons operate inside the uterus in an open procedure that partially exposes the baby to remove the tumor and give the baby a chance to survive until birth. According to scientists presenting at the American Society of Gene & Cell Therapy's special meeting on Breakthroughs in Targeted In Vivo Gene Editing, this could be avoided.
Conferences Medical technology Endocrine/metabolic Genetic/congenital Hematologic Gene therapy

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 20, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 19, 2026
  • Microscopic view of the ebola virus

    WHO declares Ebola outbreak a public health emergency of international concern

    BioWorld
    The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...
  • Acid alpha-glucosidase molecular structure isolated on black

    ‘Detargeted’ targeted gene therapy improves activity in Pompe

    BioWorld
    A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...
  • Nxera Pharma prepares and tests new GPR17 antagonists

    BioWorld Science
    Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing